Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board
WOODBRIDGE, ON, March 10, 2014 /CNW/ - Pivotal Therapeutics Inc. (OTCQX:
PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3
therapies for cardiovascular disease (CVD) and overall health, announced today
that James Connolly has been appointed to the Company's Board of Directors,
effective immediately. Mr. Connolly brings over 27 years of experience in the
pharmaceutical industry to Pivotal, including 23 years in various leadership
positions at Wyeth, formerly American Home Products, a $23 billion
pharmaceutical and health products company that was acquired by Pfizer in 2009.
During his 23 years at Wyeth, Jim served in a series of leadership roles of
increasing responsibility including Executive Vice President and General
Manager, Wyeth Vaccines, President, Wyeth Canada, Vice President - Sales and
Marketing, Area Business Director, Business Director - Wyeth/Medco joint
venture and Finance Director. Under Mr. Connolly's stewardship from 2005-2009,
Wyeth's vaccines business grew from $800 million to over $3 billion driven
principally with the creation of the first true commercial blockbuster
vaccine, Prevnar. During Jim's tenure leading Wyeth Canada, sales more than
doubled to over $650 million in less than four years, and all key promoted
brands including Effexor XR, Prevnar, Enbrel, Alesse, Premarin and BeneFix
achieved the #1 market share position in each of their respective categories.
"We are very pleased to welcome Jim to the Board of Directors of Pivotal
Therapeutics," said Dr. George Jackowski, Co-founder and Chairman of Pivotal's
Board of Directors. "Jim's wealth of experience in brand establishment,
commercialization and growing sales will be invaluable as the Company expands
its commercialization team to execute the broader launch of its Medical Food
"I am excited to be joining Pivotal's board of directors and working with the
company to help strengthen the overall commercialization efforts," stated Mr.
Connolly. "Treating an Omega-3 deficiency with an innovative Medical Food such
as VASCAZEN(®) is a unique approach to this large market and represents a
Mr. Connolly currently serves as an advisor at Crossover Healthcare Fund,
director of Vaxess Technologies and a director at Aeras, a non-profit biotech
organization developing vaccines for tuberculosis and other neglected
diseases, where he formerly served as CEO until 2013. He holds a B.S. in
Business Administration from Washington University, St. Louis, MO.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CSE: PVO) specialty
pharmaceutical company with a focus on cardiovascular disease and overall
health. Pivotal Therapeutics' lead product VASCAZEN(®) is a prescription only
Medical Food formulated to meet the dietary Omega-3 deficient needs of
patients with cardiovascular disease through elevating Eicosapentaenoic acid
(EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of
cardiovascular complications. OMAZEN(® )is a pharmaceutical grade Omega-3
providing over 90% pure Omega-3 in each capsule for the maintenance of good
health. OMAZEN(®) is a patented product available for sale and distribution
VASCAZEN(®) is currently available in the U.S. as a prescription only Medical
Food specifically formulated for the dietary management of an Omega-3
deficiency in cardiovascular patients. VASCAZEN(®) is a >90% pure Omega-3
with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series
of both U.S. and foreign patents. VASCAZEN(®) has been clinically shown to
correct an Omega-3 deficiency within eight weeks of treatment with positive
concomitant effects on the lipid profiles, mainly a 48% reduction of
triglycerides and an increase of HDL without negative impact on the LDL-C
lipid profile. VASCAZEN(®)'s results were achieved with a dose of 3 grams of
EPA and DHA per day of a prescription grade, high purity Omega-3.
The information contained in this document is as of March 10, 2014. This press
release contains forward-looking statements. Such forward-looking statements
are subject to a number of risks, assumptions and uncertainties that could
cause Pivotal's actual results to differ materially from those projected in
such forward-looking statements. These statements can be identified by the use
of words such as "will", "anticipate", "estimate", "expect", "project",
"forecast", "intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial performance
or events. In particular, factors that could cause actual results to differ
materially from those in forward looking statements include the following:
Pivotal's inability to obtain additional financing on acceptable terms; growth
in costs and expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread market
acceptance; risks relating to the Company's ability to maintain its CSE
listing. Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation to
publicly update or revise any forward-looking statements contained in this
document as a result of new information or future events or developments. CSE
has not reviewed and does not accept responsibility for the adequacy or
accuracy of this information.
SOURCE Pivotal Therapeutics Inc.
Rachelle MacSweeney President and Chief Operating Officer Phone:
Kristine DiMatteo Communications and Public Relations Manager Phone:
905-856-9797 ext. 231 E-Mail:firstname.lastname@example.org
To view this news release in HTML formatting, please use the following URL:
CO: Pivotal Therapeutics Inc.
NI: MTC NASDAQ 2575 WNEWS
-0- Mar/10/2014 13:40 GMT
Press spacebar to pause and continue. Press esc to stop.